# Myocardiaal herstel bij systolisch hartfalen met auto-antilichamen tegen β1-adrenerge receptoren

*geplaatst 2017-02-28 · Hartfalen · Journal of the American College of Cardiology · doi 10.1016/j.jacc.2016.11.067 · https://hartvaat.nl/2017/02/28/myocardiaal-herstel-bij-systolisch-hartfalen-met-auto-antilichamen-tegen-1-adren/*

Studie die myocardiaal herstel onderzocht bij HF-patiënten met auto-antilichamen tegen bèta-1-adrenerge receptoren. Onderzoekt een immunologisch subtype van hartfalen met potentieel voor gerichte therapie.

## English: Myocardial Recovery in Patients With Systolic Heart Failure and Autoantibodies Against β1-Adrenergic Receptors.

This study examined myocardial recovery in heart failure patients with autoantibodies against beta-1 adrenergic receptors, exploring an autoimmune mechanism that may identify a reversible subpopulation of dilated cardiomyopathy.

## Abstract (original, from the publication)

BACKGROUND: Among various cardiac autoantibodies (AAbs), those recognizing the β1-adrenergic receptor (β1AR) demonstrate agonist-like effects and induce myocardial damage that can be reversed by β-blockers and immunoglobulin G3 (IgG3) immunoadsorption. OBJECTIVES: The goal of this study was to investigate the role of β1AR-AAbs belonging to the IgG3 subclass in patients with recent-onset cardiomyopathy. METHODS: Peripheral blood samples were drawn at enrollment in patients with recent-onset cardiomyopathy (left ventricular ejection fraction [LVEF] ≤0.40; <6 months). The presence of IgG and IgG3-β1AR-AAb was determined, and echocardiograms were assessed, at baseline and 6 months. Patients were followed up for ≤48 months. RESULTS: Among the 353 patients who had blood samples adequate for the analysis, 62 (18%) were positive for IgG3-β1AR-AAbs (IgG3 group), 58 (16%) were positive for IgG but not IgG3 (non-IgG3 group), and the remaining were negative. There were no significant differences in baseline systolic blood pressure, heart rate, or LVEF among the groups at baseline. Left ventricular end-diastolic and end-systolic diameters were significantly larger in the non-IgG3 group compared with the other groups (left ventricular end-diastolic diameter, p < 0.01; left ventricular end-systolic diameter, p = 0.03). At 6 months, LVEF was significantly higher in the IgG3 group (p = 0.007). Multiple regression analysis showed that IgG3-β1AR-AAb was an independent predictor of LVEF at 6 months and change in LVEF over 6 months, even after multivariable adjustment (LVEF at 6 months, β = 0.20, p = 0.01; change in LVEF, β = 0.20, p = 0.008). In patients with high New York Heart Association functional class (III or IV) at baseline, the IgG3 group had a lower incidence of the composite endpoint of all-cause death, cardiac transplantation, and hospitalization due to heart failure, whereas the non-IgG3 group had the highest incidence of the composite endpoint. CONCLUSIONS: IgG3-β1AR-AAbs were associated with more favorable myocardial recovery in patients with recent-onset cardiomyopathy.

Auteurs: Yuji Nagatomo, Dennis M McNamara, Jeffrey D Alexis, Leslie T Cooper, G William Dec, Daniel F Pauly, Richard Sheppard, Randall C Starling, W H Wilson Tang

---
Bron: Journal of the American College of Cardiology, https://doi.org/10.1016/j.jacc.2016.11.067. Bijgewerkt 2026-07-03T18:38:31Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.